Markets

Clovis (CLVS) Rociletinib's Review Period Extended by FDA

Clovis Oncology, Inc.CLVS announced that the review period for rociletinib has been extended by three months by the FDA. A final decision from the regulatory authority is now expected on Jun 28, 2016.

Clovis is looking to get rociletinib approved for the treatment of patients with mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) who were previously treated with an EGFR-targeted therapy and have the EGFR T790M mutation.

We note that in May 2014, FDA granted Breakthrough Therapy designation to rociletinib. Meanwhile, the company has also submitted a marketing authorisation application for rociletinib in the EU for the same indication. A final decision is expected in mid-2016.

Why the Delay?

The FDA extended the candidate's review period after the company submitted a major amendment in response to the FDA's request for additional data for both the 500-mg and 625-mg twice-daily dosage patient groups for analyzing the efficacy of its lead pipeline candidate, rociletinib. (Read More: Clovis Crashes 70%, FDA Seeks More Data on Rociletinib )

With the delay in rociletinib's approval weighing on Clovis' prospects, however, AstraZeneca AZN stands to gain. Earlier this year, AstraZeneca gained accelerated approval in the U.S. for Tagrisso (80 mg once-daily) for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, and who have progressed on or after EGFR tyrosine kinase inhibitor therapy. This makes Tagrisso the only drug to be approved for metastatic EGFR T790M mutation-positive NSCLC.

Clovis is a Zacks Rank #3 (Hold) stock. A couple of better-ranked stocks in the health care sector are Achillion Pharmaceuticals, Inc. ACHN and Corcept Therapeutics Incorporated CORT , both sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

CORCEPT THERAPT (CORT): Free Stock Analysis Report

CLOVIS ONCOLOGY (CLVS): Free Stock Analysis Report

ACHILLION PHARM (ACHN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CORT CLVS AZN

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More